Content
All Posts > Content under Pharma/Biotech
Why Biotech ETFs Are Surging To New Highs
Video By:
Neena Mishra
Watch
Tuesday, December 10, 2019 10:00 PM EDT
We have seen very strong M&A activity in the biotech space of late and the trend is expected to continue as big pharmaceutical companies are trying to gain an edge in the increasingly competitive cancer treatment market.
Stock Charts To Watch - Tuesday, Dec. 10
Video By:
Harry Boxer
Watch
Tuesday, December 10, 2019 9:54 PM EDT
Amarin Corporation plc (AMRN) is looking well. After exploding, then pulling back and forming a wedge, AMRN finally started to trend upward in a nice pattern on Tuesday, breaking out of a wedge, and closing up 66 cents.
3 Stocks Showing Promising Technical Setups
Article By:
Jignesh Davda
Read
Sunday, December 8, 2019 12:44 PM EDT
There are three stocks I'm watching in the week ahead, Apple, Alphabet and Merck, all with setups on different time frames ranging from a weekly chart to a 4-hour chart.
Not Much Chemistry Between Sanofi And Hedge Funds
Article By:
Insider Monkey
Read
Saturday, December 7, 2019 8:43 PM EDT
Heading into the fourth quarter of 2019, a total of 27 of the hedge funds tracked by Insider Monkey were long Sanofi stock, a change of 8% from the second quarter of 2019.
US Stock Market Weekly Update December 2 - 6
Article By:
Stavros Georgiadis
Read
Saturday, December 7, 2019 7:43 PM EDT
A better than expected jobs report released on Friday was enough to send stocks higher at the close of the trading week. Economic fundamentals in the absence of rumors and statements about the US-China trade deal moved financial markets.
IBB Is Positioned For Outperformance
Article By:
Andres Cardenal
Read
Friday, December 6, 2019 8:33 AM EDT
iShares Nasdaq Biotechnology ETF is benefitting from reduced regulatory risk in the middle term. The ETF is still trading below its highs of 2015, so it has a lot of ground to recover going forward.
Never Heard Of The NEO Exchange? You're Not Alone
Article By:
Lorimer Wilson
Read
Friday, December 6, 2019 6:35 AM EDT
More and more companies have raised capital through the public markets in Canada, leading to the existence of hundreds of publicly-traded cannabis stocks - and a relatively new stock exchange.
Clovis Oncology (CLVS) Buy Level Approaching
Article By:
Gareth Soloway
Read
Thursday, December 5, 2019 2:04 PM EDT
Shares of Clovis Oncology, Inc. (CLVS) continue to retrace the massive up-move seen recently.
In this article: CLVS
November Marijuana Market Performance Sliced & Diced By Segment
Article By:
Lorimer Wilson
Read
Thursday, December 5, 2019 4:42 AM EDT
Every month I slice and dice the performance of 6 categories within the overall cannabis market to unveil the strengths and weaknesses of its components and November saw a dramatic spread in the returns of those categories
Huge Biotech M&A Premiums Narrow Perception Gap
Article By:
Lipper Alpha Insight
Read
Wednesday, December 4, 2019 6:27 AM EDT
The premiums needed to seal biotechnology acquisitions have always been high, but they’ve reached the stratosphere this year
Pitfalls Of Biotechnology Investing
Article By:
Ketan Desai
Read
Tuesday, December 3, 2019 4:53 PM EDT
How capital distorts the availability of biotechnology companies.
In this article: IBB
Canopy Growth (CGC) Bull Flag Forming
Article By:
Gareth Soloway
Read
Monday, December 2, 2019 1:48 PM EDT
Shares of marijuana player Canopy Growth continue to trade sideways to lower after an over 50% surge just a couple weeks ago.
In this article: CGC
November Performance Of The Market's 15 Cannabis ETFs Ranged From +6.1% To -14.4%
Article By:
Lorimer Wilson
Read
Monday, December 2, 2019 4:36 AM EDT
The performance of the 15 marijuana/marijuana-related ETFs varies depending on their constituents. In November this segment of the cannabis market ranged from +6.1% to -14.4% (excluding the 2 leveraged ETFs) and declined, on average, 7.3% in total.
8 Monster Stock Market Predictions For The Week Of December 2
Article By:
Michael J. Kramer
Read
Sunday, December 1, 2019 11:49 AM EDT
It will be a busy week for economic data with the ISM reports and plenty of job data likely going to decide which way the markets go. But then again, the market knows weak data will force the Fed’s hand to take action.